VJHemOnc Podcast

Leif Bergsagel, MD, Mayo Clinic, Phoenix, AZ, and Francesco Maura, MD, Sylvester Comprehensive Cancer Center, discuss genomics of high-risk and smoldering multiple myeloma. Topics cover next-generation sequencing (NGS), del(17p) and TP53 mutations, high-risk factors, controversy surrounding 17P deletion and TP53 mutation, challenges in determining and targeting cancer cells.

Charles Craddock and Christopher Hourigan discuss the important role of transplantation in AML, the value of pre-transplant MRD, and the management approaches for high-risk patients. They also explore strategies to improve outcomes for older AML patients through conditioning regimens and the introduction of cellular or drug therapies.

Dr. Anna Sureda discusses the current role of chemotherapy in Hodgkin and non-Hodgkin lymphoma and how novel therapies such as CAR-T cells and antibodies are changing the treatment landscape. The podcast explores the standard of care, chemo-free strategies, targeted therapies, and the potential replacement of autologous stem cell transplantation with CAR-TIs in high-risk patients.

Experts Amer Zeidan and Sanam Loghavi discuss the updated ICC and WHO classifications for MDS. They explore the overlap and differences between the two systems and highlight the challenges in classifying MDS. The podcast also emphasizes the importance of a comprehensive report and the potential of AI in generating such reports. The significance of a uniform classification for MDS and its impact on clinical practice is highlighted, along with the need for improved treatments. Lastly, the podcast emphasizes the importance of providing accurate patient education resources and recognizing genetic abnormalities morphologically.

Experts discuss strategies for minimizing cytokine release syndrome (CRS) and immune effect cell associated neurotoxicity syndrome (ICANS) in CAR T cell therapy. They explore treatment approaches for severe and refractory CRS, including the use of medications like anakinera and cetuximab. The podcast also covers the management of toxicities associated with CAR-T therapy, recommendations for managing early and late infections, and the use of GCSE stimulation and intravenous immunoglobulin substitution.

Experts Arnon Nagler, MD and Maksim Mamonkin, PhD discuss the growing role of immunotherapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). They explore the use of novel immunotherapies like CAR-T cells, antibody-drug conjugates, and monoclonal antibodies, as well as the possibility of moving away from stem cell transplantation. Topics covered include targeting CD7 in T-ALL, chemotherapy-free regimens, and the future of ALL treatment.

Learn about the challenges of CAR-T therapy in CLL and the possibilities of combining it with ibrutinib. Discover the latest advances in CAR-T therapy for Richter's transformation and the slower development of CAR-T therapy in CLL compared to other diseases.

Experts Charles Craddock, Shernan Holtan, and Anna Sureda discuss GvHD and other post-transplant complications. They highlight the importance of addressing these complications and explore approaches to GvHD prophylaxis and treatment including regenerative medicine and different drug strategies.

Experts discuss the prognostic role and value of MRD in multiple myeloma, the potential benefits of adjusting treatment based on MRD results, and using MRD to personalize therapy for patients.

Experts discuss the challenges and promise of bringing CAR-T therapy to MDS patients. Difficulties in applying CAR T therapy include target identification and immunosuppressive microenvironment. Creating effective CAR T cell therapies for myeloid malignancies requires a uniform target antigen and T cell fitness and function.